Antisoma: Data from AS1404 lung cancer trial show survival benefit

By E. Janene Geiss

Philadelphia, Sept. 27 - Antisoma plc said Wednesday that final data from its phase 2 trial of AS1404 in non-small cell lung cancer show a very substantial survival benefit.

Patients who received AS1404 on top of standard chemotherapy had a median survival of 14 months, compared with 8.8 months in patients treated with chemotherapy alone, the London biopharmaceutical company said in a news release.

This 5.2-month difference is one of the largest ever seen in a randomized, controlled trial combining a novel agent with first-line chemotherapy for lung cancer. Across the trial's duration, patients treated with AS1404 had a 27% lower risk of dying than those receiving chemotherapy alone.

Safety data from the trial also were encouraging. The addition of AS1404 to chemotherapy was well-tolerated. These findings extend those announced in June and strongly support Antisoma's plans for a phase 3 trial in lung cancer, the company said.

The lung cancer study is one of three phase 2 trials of AS1404. Positive response data recently were announced from a trial in prostate cancer, and encouraging early data have been presented from an ovarian cancer study.

Antisoma said it is in talks with a number of companies with a view to licensing AS1404.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.